The Malignant Germ Cell International Consortium (MaGIC) was launched in 2009 when the Children’s Oncology Group (US) and the Children’s Cancer and Leukaemia Group (UK) signed a Memorandum of Understanding to combine data from seven clinical trials that were conducted between 1983-2009.
MaGIC’s first annual meeting took place in 2010 in Boston, Massachusetts.
In 2015, MaGIC published Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States, which derived from the MaGIC Data Commons. The revised risk classification, which includes both pediatric and adolescent patients, was developed to serve as the basis for future international collaborative trials. To date, MaGIC has opened one trial using the revised risk classification (AGCT1531) but has also influenced other open trials to revise their studies to allow for younger patient enrollment (AO31102 and AGCT1532).